G1/S cell cycle proteins as markers of aggressive prostate carcinoma

Urology

Volumn 55, Issue 3, 2000, Pages 316-322

  Kibel, Adam S ^a,b   Isaacs, William B ^a,b  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b DEPARTMENT OF PATHOLOGY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BIOCHEMICAL MARKER; CELL CYCLE PROTEIN; CYCLIN A; CYCLIN B; CYCLIN D; CYCLIN D1; CYCLIN E; PROSTATE SPECIFIC ANTIGEN; PROTEIN P16; PROTEIN P21; PROTEIN P27; PROTEIN P53; RETINOBLASTOMA PROTEIN;

CANCER GROWTH; CANCER STAGING; CELL CYCLE G1 PHASE; CELL CYCLE S PHASE; DISEASE COURSE; GENE LOCUS; GENE MUTATION; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LYMPH NODE METASTASIS; MALE; PRIORITY JOURNAL; PROSTATE CARCINOMA; REVIEW; RISK ASSESSMENT; RISK FACTOR; SEMINAL VESICLE DISEASE; TUMOR CELL LINE;

CELL CYCLE PROTEINS; CYCLIN-DEPENDENT KINASES; CYCLINS; G1 PHASE; HUMANS; MALE; PROSTATIC NEOPLASMS; RETINOBLASTOMA PROTEIN; S PHASE; TUMOR MARKERS, BIOLOGICAL; TUMOR SUPPRESSOR PROTEIN P53;

EID: 0033952122     PISSN: 00904295     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0090-4295(99)00478-1     Document Type: Review

References (50)

1. Partin A.W., Kattan M.W., Subong E.N., et al. Combination of prostate-specific antigen, clinical stage, and Gleason score to predict pathological stage of localized prostate cancer. A multi-institutional update. JAMA. 277:1997;1445-1451.
2. Kattan M.W., Eastham J.A., Stapleton A.M., et al. A preoperative nomogram for disease recurrence following radical prostatectomy for prostate cancer. J Natl Cancer Inst. 90:1998;766-771.
3. Elledge S.J. Cell cycle checkpoints preventing an identity crisis . Science. 274:1996;1664-1672.
4. Clurman B.E., Porter P. New insights into the tumor suppression function of P27(kip1). Proc Natl Acad Sci U S A. 95:1998;15158-15160.
5. Nasmyth K. Viewpoint putting the cell cycle in order . Science. 274:1996;1643-1645.
6. Sherr C.J. Cancer cell cycles. Science. 274:1996;1672-1677.
7. Dyson N. The regulation of E2F by pRB-family proteins. Genes Dev. 12:1998;2245-2262.
8. Levine A.J. p53, the cellular gatekeeper for growth and division. Cell. 88:1997;323-331.
9. Friend S.H., Bernards R., Rogelj S., et al. A human DNA segment with properties of the gene that predisposes to retinoblastoma and osteosarcoma. Nature. 323:1986;643-646.
10. Bookstein R., Rio P., Madreperla S.A., et al. Promoter deletion and loss of retinoblastoma gene expression in human prostate carcinoma. Proc Natl Acad Sci U S A. 87:1990;7762-7766.
11. Bookstein R., Shew J.Y., Chen P.L., et al. Suppression of tumorigenicity of human prostate carcinoma cells by replacing a mutated RB gene. Science. 247:1990;712-715.
12. Brooks J.D., Bova G.S., Isaacs W.B. Allelic loss of the retinoblastoma gene in primary human prostatic adenocarcinomas. Prostate. 26:1995;35-39.
13. Phillips S.M., Barton C.M., Lee S.J., et al. Loss of the retinoblastoma susceptibility gene (RB1) is a frequent and early event in prostatic tumorigenesis. Br J Cancer. 70:1994;1252-1257.
14. Vesalainen S., Lipponen P. Expression of retinoblastoma gene (Rb) protein in T12M0 prostatic adenocarcinoma. J Cancer Res Clin Oncol. 121:1995;429-433.
15. Ittmann M.M., Wieczorek R. Alterations of the retinoblastoma gene in clinically localized, stage B prostate adenocarcinomas. Hum Pathol. 27:1996;28-34.
16. Tricoli J.V., Gumerlock P.H., Yao J.L., et al. Alterations of the retinoblastoma gene in human prostate adenocarcinoma. Genes Chromosom Cancer. 15:1996;108-114.
17. Theodorescu D., Broder S.R., Boyd J.C., et al. p53, bcl-2 and retinoblastoma proteins as long-term prognostic markers in localized carcinoma of the prostate. J Urol. 158:1997;131-137.
18. Morgan D.O. Principles of CDK regulation. Nature. 374:1995;131-134.
19. 1/S phase transition by expression of cyclins D1 and E with an inducible system. Mol Cell Biol. 14:1994;1669-1679.
20. Strauss M., Lukas J., Bartek J. Unrestricted cell cycling and cancer. Nat Med. 1:1995;1245-1246.
21. Mashal R.D., Lester S., Corless C., et al. Expression of cell cycle-regulated proteins in prostate cancer. Cancer Res. 56:1996;4159-4163.
22. Kallakury B.V., Sheehan C.E., Ambros R.A., et al. The prognostic significance of p34cdc2 and cyclin D1 protein expression in prostate adenocarcinoma. Cancer. 80:1997;753-763.
23. Han E.K., Lim J.T., Arber N., et al. Cyclin D1 expression in human prostate carcinoma cell lines and primary tumors. Prostate. 35:1998;95-101.
24. Aaltomaa S., Eskelinen M., Lipponen P. Expression of cyclin A and D proteins in prostate cancer and their relation to clinopathological variables and patient survival. Prostate. 38:1999;175-182.
25. Komiya A., Suzuki H., Aida S., et al. Mutational analysis of CDKN2 (CDK4I/MTS1) gene in tissues and cell lines of human prostate cancer. Jpn J Cancer Res. 86:1995;622-625.
26. Park D.J., Wilczynski S.P., Pham E.Y., et al. Molecular analysis of the INK4 family of genes in prostate carcinomas. J Urol. 157:1997;1995-1999.
27. Jarrard D.F., Bova G.S., Ewing C.M., et al. Deletional, mutational, and methylation analyses of CDKN2 (p16/MTS1) in primary and metastatic prostate cancer. Genes Chromosom Cancer. 19:1997;90-96.
28. Chi S.G., deVere White R.W., Muenzer J.T., et al. Frequent alteration of CDKN2 (p16(INK4A)/MTS1) expression in human primary prostate carcinomas. Clin Cancer Res. 3:1997;1889-1897.
29. Shiohara M., el-Deiry W.S., Wada M., et al. Absence of WAF1 mutations in a variety of human malignancies. Blood. 84:1994;3781-3784.
30. Aaltomaa S., Lipponen P., Eskelinen M., et al. Prognostic value and expression of p21(waf1/cip1) protein in prostate cancer. Prostate. 39:1999;8-15.
31. Matsushima H., Sasaki T., Goto T., et al. Immunohistochemical study of p21WAF1 and p53 proteins in prostatic cancer and their prognostic significance. Hum Pathol. 29:1998;778-783.
32. Byrne R.L., Horne C.H., Robinson M.C., et al. The expression of waf-1, p53 and bcl-2 in prostatic adenocarcinoma. Br J Urol. 79:1997;190-195.
33. Kawamata N., Morosetti R., Miller C.W., et al. Molecular analysis of the cyclin-dependent kinase inhibitor gene p27/Kip1 in human malignancies. Cancer Res. 55:1995;2266-2269.
34. Kibel A.S., Freije D., Isaacs W.B., et al. Deletion mapping at 12p12-13 in metastatic prostate cancer. Genes Chromosom Cancer. 25:1999;270-276.
35. Guo Y., Sklar G.N., Borkowski A., et al. Loss of the cyclin-dependent kinase inhibitor p27(Kip1) protein in human prostate cancer correlates with tumor grade. Clin Cancer Res. 3:1997;2269-2274.
36. Cordon-Cardo C., Koff A., Drobnjak M., et al. Distinct altered patterns of p27KIP1 gene expression in benign prostatic hyperplasia and prostatic carcinoma. J Natl Cancer Inst. 90:1998;1284-1291.
37. Cote R.J., Shi Y., Groshen S., et al. Association of p27Kip1 levels with recurrence and survival in patients with stage C prostate carcinoma. J Natl Cancer Inst. 90:1998;916-920.
38. Cheville J.C., Lloyd R.V., Sebo T.J., et al. Expression of p27kip1 in prostatic adenocarcinoma. Mod Pathol. 11:1998;324-328.
39. Isaacs W.B., Carter B.S., Ewing C.M. Wild-type p53 suppresses growth of human prostate cancer cells containing mutant p53 alleles. Cancer Res. 51:1991;4716-4720.
40. Chi S.G., deVere White R.W., Meyers F.J., et al. p53 in prostate cancer frequent expressed transition mutations . J Natl Cancer Inst. 86:1994;926-933.
41. Heidenberg H.B., Bauer J.J., McLeod D.G., et al. The role of the p53 tumor suppressor gene in prostate cancer a possible biomarker? Urology. 48:1996;971-979.
42. Navone N.M., Troncoso P., Pisters L.L., et al. p53 protein accumulation and gene mutation in the progression of human prostate carcinoma. J Natl Cancer Inst. 85:1993;1657-1669.
43. Thomas D.J., Robinson M., King P., et al. p53 expression and clinical outcome in prostate cancer. Br J Urol. 72:1993;778-781.
44. Visakorpi T., Kallioniemi O.P., Heikkinen A., et al. Small subgroup of aggressive, highly proliferative prostatic carcinomas defined by p53 accumulation. J Natl Cancer Inst. 84:1992;883-887.
45. Stricker H.J., Jay J.K., Linden M.D., et al. Determining prognosis of clinically localized prostate cancer by immunohistochemical detection of mutant p53. Urology. 47:1996;366-369.
46. Bauer J.J., Sesterhenn I.A., Mostofi F.K., et al. Elevated levels of apoptosis regulator proteins p53 and bcl-2 are independent prognostic biomarkers in surgically treated clinically localized prostate cancer. J Urol. 156:1996;1511-1516.
47. Grignon D.J., Caplan R., Sarkar F.H., et al. p53 status and prognosis of locally advanced prostatic adenocarcinoma a study based on RTOG 8610 . J Natl Cancer Inst. 89:1997;158-165.
48. Brooks J.D., Bova G.S., Ewing C.M., et al. An uncertain role for p53 gene alterations in human prostate cancers. Cancer Res. 56:1996;3814-3822.
49. Huang A., Gandour-Edwards R., Rosenthal S.A., et al. p53 and bcl-2 immunohistochemical alterations in prostate cancer treated with radiation therapy. Urology. 51:1998;346-351.
50. Bauer J.J., Connelly R.R., Sesterhenn I.A., et al. Biostatistical modeling using traditional variables and genetic biomarkers for predicting the risk of prostate carcinoma recurrence after radical prostatectomy. Cancer. 79:1997;952-962.